

13 August 2025

To whom it may concern:

### Explanation of Fluctuations in Business Performance in the Q2 2025 Financial Report

Tipharco Pharmaceutical Joint Stock Company (DTG) hereby provides an explanation to the State Securities Commission, the Hanoi Stock Exchange, and esteemed shareholders regarding the fluctuations in revenue and profit after tax as presented in the reviewed financial statements for the six-month period ended 30 June 2025 compared to the same period in 2024, as follows:

Unit: VND

No	Indicator	6M 2025	6M 2024	2025/2024
1	Net Revenue	124.247.993.893	149.689.844.582	83,00%
2	Cost of Goods Sold	100.116.771.982	114.904.438.876	87,13%
3	Gross Profit	24.131.221.911	34.785.405.706	69,37%
4	Net Profit	575.074.350	11.777.930.928	4,88%
5	Profit Before Tax	746.153.275	12.061.977.696	6,19%
6	Profit After Tax	635.547.474	10.002.638.250	6,35%

Source: Financial statements for the six-month period ended 30 June 2025

In the first half of 2025, the pharmaceutical industry faced a series of challenges: declining consumer demand, exchange rate volatility, rising input costs, and increasingly intense competition within the sector. In particular, slower consumption in traditional markets directly impacted the Company's business performance.

To maintain market share and support its distribution network during this difficult period, the Company proactively implemented a range of diversified sales policies tailored to each customer segment. However, net revenue reached only about 83% of the level recorded in the same period last year. The revenue decline also led to lower production volumes in the first six months of 2025 compared to the same period in 2024, thereby increasing production costs per unit. In addition, the exchange rate in 2025 rose significantly compared to 2024. These factors resulted in the cost of goods sold decreasing at a slower pace than revenue. The combination of lower sales and narrower margins had a significant negative impact on profit after tax.

Nevertheless, a key highlight was the accelerated collection of receivables and the prioritization of loan repayments. These factors demonstrate the Company's ability to generate healthy cash flows, strengthen its financial position, and reduce liquidity risk. This provides a solid foundation for the Company to implement growth recovery initiatives and enhance operational efficiency in the coming quarters.

Despite the underperformance in profit after tax during the period, the Company remains committed to a strategy of proactive adaptation, seeking to balance revenue growth objectives with financial stability. In the upcoming quarters, the Company will continue to:

- Review the effectiveness of promotional programs and sales policies;
- Restructure the product portfolio, prioritizing product lines with high profit margins and strong growth potential;
- Maintain stable cash flow while enhancing operational flexibility to promptly adapt to market developments.

Thank you very much./.



Note: This document has been translated from the Vietnamese original for reference purposes only. In the event of any discrepancy between this translated document and the Vietnamese original, the original shall prevail.

# **TIPHARCO PHARMACEUTICAL JOINT STOCK COMPANY**

Reviewed Interim Financial Statements  
For the six-month period ended 30 June 2025



## TABLE OF CONTENTS

	Page
<b>THE REPORT OF THE BOARD OF GENERAL DIRECTORS</b>	1 – 4
<b>REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION</b>	5 – 6
<b>REVIEWED INTERIM FINANCIAL STATEMENTS</b>	
Interim balance sheet	7 – 10
Interim income statement	11
Interim cash flow statement	12 – 13
Notes to the interim financial statement	14 – 40

## REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

The Board of General Directors of Tipharco Pharmaceutical Joint Stock Company (briefly called "the Company") has the pleasure in presenting this report and the Company's Reviewed Financial Interim Financial Statements for the six-month period ended 30 June 2025.

### 1. General information

Tipharco Pharmaceutical Joint Stock Company was established in Vietnam and operating under the Registration Certificate No. 1200100557, first registered on February 28, 2006, and registered for the 22nd change on July 16, 2024, issued by the Department of Planning and Investment of Dong Thap province.

The Company's shares with stock code DTG are listed on the Hanoi Stock Exchange under Decision No. 841/QĐ-SGDHN dated July 24, 2024:

Type of shares	: Ordinary Share
Trading code	: DTG
Par value per share	: VND 10,000/share
Number of listed shares	: 8,352,573 shares
The total value of listed shares at par value	: VND 83,525,730,000

Head office:

- Address : Lot 08, 09 Tan My Chanh Industrial and Handicraft Cluster, My Phong Ward, Dong Thap Province, Vietnam.  
(former address is Lot 08, 09 Tan My Chanh Industrial and Handicraft Cluster, Ward 9, My Tho City, Tien Giang Province, Vietnam)
- Telephone : 0273 3 871 817
- Fax : 0273 3 885 040

According to business registration Certificate, the company's business activities are:

- Real estate business, land use rights owned by the owner, user, or lessee;  
Details: Leasing land use rights, house ownership rights, and assets attached to land in cases where the State leases land; Buying, selling, leasing houses and land use rights not for residence. (excluding: not performing the activity of "investing in building infrastructure for cemeteries and graveyards to transfer land use rights attached to infrastructure").
- Warehousing and storage of goods;  
Details: Warehouses for storing ordinary goods, cold storage.
- Other professional, scientific and technological activities not elsewhere classified;  
Details: Technology transfer and technology transfer services; Product research and development services.
- Production of cosmetics, soaps, detergents, polishes, and cleaning products;  
Details: Production of cosmetics.
- Production of non-alcoholic beverages, mineral water;  
Details: Production of all kinds of soft drink syrups. Production of bottled and jarred purified water of all kinds.
- Other specialized wholesale not elsewhere classified;  
Details: Trading, importing, and exporting chemicals. (excluding: not performing distribution activities of goods that economic organizations with foreign investors are not entitled to distribute according to legal regulations at each time).
- Distilling, refining, and blending all kinds of strong alcohol;  
Details: Production of all kinds of bottled medicinal wine.
- Retailing of medicines, medical equipment, cosmetics, and hygiene products in specialized stores;  
Details: Retailing of medicines and products manufactured by the Company; Retailing of medical supplies, equipment, and medical instruments in the medical and pharmaceutical sectors; cosmetics and functional foods (excluding: not distributing goods that economic organizations with foreign investors are not allowed to distribute according to the provisions of law from time to time).



**REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION**

## - Wholesale of beverages;

Details: Trading in bottled and jarred purified water of all kinds. Trading in soft drink syrups. Trading in bottled medicinal wines of all kinds. (excluding: not distributing goods that economic organizations with foreign investors are not allowed to distribute according to the provisions of law from time to time).

## - Manufacturing of medicines, pharmaceutical chemicals, and medicinal materials;

Details: Manufacturing of medicines of all kinds. Manufacturing of pharmaceutical chemicals and medicinal materials. Manufacturing of plant products for medicinal purposes.

## - Wholesale of other household appliances;

Details: Trading, importing, and exporting pharmaceuticals and medical supplies, production, and business equipment in the medical sector; Trading, importing, and exporting cosmetics; Trading, importing, and exporting medical instruments. (excluding: not performing distribution activities of goods that economic organizations with foreign investors are not entitled to distribute according to legal regulations at each time).

## - Electricity production;

Details: Electricity production from solar energy.

## - Electricity transmission and distribution;

Details: Electricity transmission. Electricity distribution (excluding: not performing transmission activities, regulating the National Power System).

## - Manufacturing medical, dental, orthopedic, and rehabilitation equipment and instruments;

Details: Manufacturing medical equipment and instruments.

## - Activities of general, specialized, and dental clinics;

Details: Activities of general and specialized clinics.

- Production of vaccines, biological products, cosmetics, preparations, and packaging. Trading, importing, and exporting raw materials. Trading, importing, and exporting vaccines, biological products, preparations, and packaging. Processing, franchising in the production and business of pharmaceuticals, medical supplies, functional foods, vaccines, biological products, cosmetics, preparations, raw materials, chemicals, packaging, production, and business equipment in the medical sector. Production, trading, export, and import of functional foods. Production of essential oils from herbs. (excluding: not performing distribution activities of goods that economic organizations with foreign investors are not entitled to distribute according to legal regulations at each time).

During the period, the Company's main activities are as follows: Manufacturing of pharmaceuticals, chemicals, and medicinal materials, details: manufacturing of pharmaceuticals; manufacturing of chemicals and medicinal materials; manufacturing of plant products for medicinal purposes.

## 2. The members of the Board of Management, Board of Supervisors, Board of General Directors and Chief Accountant

The members of the Board of Management, Board of Supervisors, Board of General Directors and Chief Accountant during the period and to the date of this report are:

### The Board of Management

<u>Name</u>	<u>Position</u>	
Mr. Dang Viet Anh	Chairman	
Mr. Le Thanh Tung	Deputy chairman	
Ms. Dang Thi Thu Hang	Member	
Ms. Ly Thi Xuan Mai	Member	
Ms. Nguyen The Hong Nhung	Member	(Appointing Date at 18 April 2025)
Mr. Do Ngoc An	Member	(Appointing Date at 18 April 2025)
Mr. Luu Hoai Nam	Member	(Resigning Date at 18 April 2025)
Ms. Tran Thi Kieu Tien	Member	(Resigning Date at 18 April 2025)
Mr. Nguyen Quoc Khanh	Independent member	
Mr. Thai Van Hung	Independent member	

## REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

### Board of Supervisors

<u>Name</u>	<u>Position</u>
Mr. Dong Hai Ha	Chief Supervisor
Ms. Tran Thi Bich Nhi	Deputy Supervisor
Mr. Hoang Quoc Trung	Member (Appointing Date at 18 April 2025)
Mr. Le Van Son	Member (Resigning Date at 18 April 2025)

### Board of General Directors

<u>Name</u>	<u>Position</u>
Mr. Le Thanh Tung	General Director
Ms. Ly Thi Xuan Mai	Deputy General Director

### Chief Accountant

<u>Name</u>	<u>Position</u>
Mrs. Le Thi My Tien	Chief Accountant

### Legal representative

<u>Name</u>	<u>Position</u>
Mr. Dang Viet Anh	Chairman
Mr. Le Thanh Tung	General Director

### 3. The Company's financial position and operating results

The Company's financial position as at 30 June 2025 and its operating result for the fiscal period ended are presented in the accompanying interim financial statements.

### 4. Events subsequent to the balance sheet date

There have been no significant events occurring after the balance sheet date which would require adjustments or disclosures to be made in the interim financial statements.

### 5. Auditors

AFC Vietnam Auditing Company Limited - Can Tho Branch has been appointed to audit the interim financial statements for the fiscal period ended 30 June 2025.

### 6. Statement of the Board General Directors' responsibility in respect of the interim financial statements

The Board of General Directors is responsible for the interim financial statements for the fiscal period ended 30 June 2025, which gives a true and fair view of the state of affair of the Company and of its interim results of operations and interim cash flows for the fiscal period ended 30 June 2025. In preparing those interim financial statements, the Board of General Directors is required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the interim financial statements;
- Prepare the interim financial statements on the going concern basic unless it is inappropriate to presume that the Company will continue in business; and
- Design, implement and maintain the Company's internal control for prevention and detection of fraud and error.

## **REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION**

The Board of General Directors is responsible for ensuring that the proper accounting records are kept which disclose to give true and fair view of the Company's financial position, operating opposite, with reasonable accuracy at any time, and to ensure that the accounting records comply with the Vietnamese Accounting Standards. The Board of General Directors is also responsible for controlling the assets of the Company and therefore has taken the appropriate measures for the prevention and detection of fraud and other irregularities.

The Board of General Directors confirms that the Company has complied with the above requirements in preparing the interim financial statements.

### **7. Approval of the interim financial statements**

The Board of General Directors hereby approve the accompanying interim financial statements which give a true and fair view of the financial position of the Company as at 30 June 2025, the results of its operations and cash flows and the accompanying explanatory notes of the Company for the period then ended in accordance with the Vietnamese Accounting Standards, the current Vietnamese Accounting System for Business Entities and relevant statutory requirements.

On behalf of the Board of General Directors,



Mr. Le Thanh Tung

General Director

Dong Thap, 11 August 2025





Công ty TNHH Kiểm Toán AFC Việt Nam  
AFC Vietnam Auditing Co., Ltd.

Thành viên tập đoàn PKF Quốc tế  
Member firm of PKF International



Accountants &  
business advisers

No.: 048/2025/BCSX-CT.00007

## REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

**To: The members of the Board of Management and the Board of General Directors  
TIPHARCO PHARMACEUTICAL JOINT STOCK COMPANY**

We have reviewed the Interim Financial Statement of Tipharco Pharmaceutical Joint Stock Company ("the Company"), prepared on 11 August 2025, as set out on pages 7 to 40, including: Interim statement of financial position as at 30 June 2025, Interim statement of comprehensive income, Statement of cash flows the financial period ended 30 June 2025 and Notes to the interim financial statements.

### The Board of General Director's Responsibility

The Board of General Directors is responsible for the preparation and true and fair presentation of these financial statements of the Company in accordance with Vietnamese Accounting Standards, accounting regime for enterprise and relevant statutory requirements and for such internal control as the Board of General Directors determines is necessary to enable the preparation and presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility

Auditor's responsibility give a conclusion about the Interim Financial Statements based on our review. We conducted 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Auditor conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Interim Financial Information does not give a true and fair of the financial position of Tipharco Pharmaceutical Joint Stock Company as at 30 June 2025, and of its financial performance and its cash flows of the period ended in accordance with the Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to preparation and presentation of Interim Financial Statements.

## REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION (cont.)

### Other matter

The Financial Statements of Tipharco Pharmaceutical Joint Stock Company for the six months ended June 30, 2024, and for the year ended December 31, 2024, have been reviewed and audited by another auditor and another auditing firm. The auditor expressed an unqualified audit opinion on those financial statements on August 12, 2024 and March 21, 2025.



**TRANG ĐAC NHA**

**Director**

Audit Practicing Registration Certificate No.: 2111-2023-009-1

*Authorized person for*

**AFC VIET NAM AUDITING COMPANY LIMITED – CAN THO BRANCH**

Can Tho City, August 11, 2025

**INTERIM BALANCE SHEET**

As at 30 June 2025

Currency Unit: VND

	Code	Notes	30/06/2025	01/01/2025
<b>ASSETS</b>				
<b>CURRENT ASSETS</b>	<b>100</b>		<b>173,762,727,366</b>	<b>229,500,850,814</b>
<b>Cash and cash equivalents</b>	<b>110</b>	5.1	<b>13,105,132,737</b>	<b>16,360,889,595</b>
Cash	111		13,105,132,737	16,360,889,595
Cash equivalents	112		-	-
<b>Short term financial investments</b>	<b>120</b>		-	-
Trading securities	121		-	-
Provision for diminution in value of trading securities	122		-	-
Held-to-maturity investments	123		-	-
<b>Short-term receivables</b>	<b>130</b>		<b>62,013,217,042</b>	<b>108,504,362,863</b>
Short-term accounts receivable	131	5.2	62,535,651,333	107,875,457,413
Short-term advances to suppliers	132	5.3	367,498,900	1,484,740,870
Short-term inter-company receivables	133		-	-
Construction contract receivables based on progress billings	134		-	-
Receivable from short-term loans	135		-	-
Other short-term receivables	136	5.4.1	500,690,808	98,575,456
Provision for doubtful short-term debts	137	5.5	(1,390,623,999)	(954,410,876)
Deficient assets pending resolution	139		-	-
<b>Inventories</b>	<b>140</b>	5.6	<b>98,150,232,898</b>	<b>104,450,741,473</b>
Inventories	141		98,361,983,607	105,244,836,291
Provision for devaluation in inventories	149		(211,750,709)	(794,094,818)
<b>Other short-term assets</b>	<b>150</b>		<b>494,144,689</b>	<b>184,856,883</b>
Short-term prepayments	151	5.7.1	477,990,305	184,856,883
VAT deductibles	152		-	-
Other receivables from State budget	153	5.13	16,154,384	-
Transactions to buy, resell government bonds	154		-	-
Other short-term assets	155		-	-

**INTERIM BALANCE SHEET**

As at 30 June 2025

Currency Unit: VND

	Code	Notes	30/06/2025	01/01/2025
<b>NON-CURRENT ASSETS</b>	<b>200</b>		<b>101,962,673,886</b>	<b>107,328,943,801</b>
<b>Long-term receivables</b>	<b>210</b>		<b>305,895,000</b>	<b>305,895,000</b>
Long-term receivables from customers	211		-	-
Long-term advances to suppliers	212		-	-
Business capital in dependent units	213		-	-
Long-term inter-company receivables	214		-	-
Receivable from long-term loans	215		-	-
Other long-term receivables	216	5.4.2	305,895,000	305,895,000
Provision for doubtful long-term debt	219		-	-
<b>Fixed assets</b>	<b>220</b>		<b>92,627,067,312</b>	<b>97,526,831,759</b>
Tangible fixed assets	221	5.8	92,077,067,312	96,976,831,759
Cost	222		202,779,789,982	202,174,138,982
Accumulated depreciation	223		(110,702,722,670)	(105,197,307,223)
Finance leases fixed assets	224		-	-
Cost	225		-	-
Accumulated depreciation	226		-	-
Intangible fixed assets	227	5.9	550,000,000	550,000,000
Cost	228		550,000,000	550,000,000
Accumulated amortization	229		-	-
<b>Investment property</b>	<b>230</b>		-	-
Cost	231		-	-
Accumulated depreciation	232		-	-
<b>Long-term assets in progress</b>	<b>240</b>		-	-
Long-term works in progress	241		-	-
Construction in progress	242		-	-
<b>Long-term financial investments</b>	<b>250</b>		-	-
Investment in subsidiaries	251		-	-
Investment in joint ventures, associates	252		-	-
Investments in other entities	253		-	-
Provision for diminution in value of long-term financial investments	254		-	-
Long-term investments held to maturity	255		-	-
<b>Other long-term assets</b>	<b>260</b>		<b>9,029,711,574</b>	<b>9,496,217,042</b>
Long-term prepaid expenses	261	5.7.2	8,470,171,633	8,897,014,237
Deferred income tax assets	262	5.10	559,539,941	599,202,805
Long-term equipment, spare parts for replacement	263		-	-
Other non-current assets	268		-	-
<b>TOTAL ASSETS</b>	<b>270</b>		<b>275,725,401,252</b>	<b>336,829,794,615</b>

**INTERIM BALANCE SHEET**

As at 30 June 2025

Currency Unit: VND

	Code	Notes	30/06/2025	01/01/2025
<b>RESOURCES</b>				
<b>LIABILITIES</b>	<b>300</b>		<b>89,031,790,672</b>	<b>150,771,731,509</b>
<b>Current liabilities</b>	<b>310</b>		<b>88,361,465,672</b>	<b>150,044,223,176</b>
Trade accounts payable	311	5.11	23,988,967,140	18,976,823,385
Short-term advance from customers	312	5.12	4,208,273,231	5,448,623,515
Taxes and payables to the State Budget	313	5.13	979,908,110	4,846,444,496
Payables to employees	314		2,616,403,736	5,544,489,515
Short-term accrued expenses	315	5.14	571,138,947	903,909,836
Short-term inter-company payables	316		-	-
Construction contract payables based on progress billings	317		-	-
Short-term unrealized revenues	318		-	-
Other current payables	319	5.15	3,956,042,800	2,771,295,600
Short-term loans and finance lease liabilities	320	5.16	51,780,787,055	111,292,692,176
Provision for short-term payables	321		-	-
Bonus and welfare funds	322	5.17	259,944,653	259,944,653
Price Stabilization Fund	323		-	-
Transactions to buy, resell government bonds	324		-	-
<b>Long-term liabilities</b>	<b>330</b>		<b>670,325,000</b>	<b>727,508,333</b>
Long-term trade payables	331		-	-
Long-term advance from customers	332		-	-
Long-term accrued expenses	333		-	-
Inter-company payables on capital	334		-	-
Long-term payables to inter-company	335		-	-
Long-term unrealized revenues	336		-	-
Other long-term payables	337		-	-
Long-term loans and finance lease liabilities	338		-	-
Convertible bonds	339		-	-
Preferred shares	340		-	-
Deferred income tax liabilities	341		-	-
Provision for long-term payables	342	5.18	670,325,000	727,508,333
Science and technology development fund	343		-	-



TIPHARCO PHARMACEUTICAL JOINT STOCK COMPANY

Lot 08, 09 Tan My Chanh Industrial and Handicraft Cluster, My Phong Ward, Dong Thap Province, Vietnam

**INTERIM BALANCE SHEET**

As at 30 June 2025

Currency Unit: VND

	Code	Notes	30/06/2025	01/01/2025
<b>RESOURCES</b>				
<b>OWNER'S EQUITY</b>	<b>400</b>		<b>186,693,610,580</b>	<b>186,058,063,106</b>
<b>Capital</b>	<b>410</b>	5.19	<b>186,693,610,580</b>	<b>186,058,063,106</b>
Owners' invested capital	411		83,525,730,000	83,525,730,000
- Ordinary shares with voting rights	411a		83,525,730,000	83,525,730,000
- Preferred shares	411b		-	-
Capital surplus	412		33,634,115,000	33,634,115,000
Convertible bonds option	413		-	-
Other owner's capital	414		-	-
Treasury stocks	415		-	-
Assets revaluation difference	416		-	-
Foreign exchange difference	417		-	-
Investment and development funds	418		19,313,275,717	19,313,275,717
Business arrangements support fund	419		-	-
Other owner's funds	420		-	-
Retained earnings	421		50,220,489,863	49,584,942,389
- Retained earnings brought forward	421a		49,584,942,389	26,447,598,584
- Retained earnings for the current year	421b		635,547,474	23,137,343,805
Construction capital sources	422		-	-
<b>Other resources and other funds</b>	<b>430</b>		<b>-</b>	<b>-</b>
Funds	431		-	-
Funds for fixed assets acquisition	432		-	-
<b>TOTAL RESOURCES</b>	<b>440</b>		<b>275,725,401,252</b>	<b>336,829,794,615</b>

**PHAM THI THU LANH**  
Preparer

**LE THI MY TIEN**  
Chief Accountant



**LE THANH TUNG**  
General Director  
Dong Thap, 11 August 2025

**INTERIM INCOME STATEMENT**

For the six-month period ended 30 June 2025

Currency Unit: VND

INDEX	Code	Notes	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
Revenue from sales of goods and services rendered	01	6.1.1	127,536,442,904	150,458,863,097
Less deductions	02	6.1.1	3,288,449,011	769,018,515
Net revenue from sales of goods and services rendered	10		124,247,993,893	149,689,844,582
Cost of goods sold	11	6.2	100,116,771,982	114,904,438,876
Gross profit from sales of goods and services rendered	20		24,131,221,911	34,785,405,706
Financial income	21	6.3	179,669,877	26,104,842
Financial expenses	22	6.4	2,934,022,396	2,411,041,564
<i>In which: Interest expenses</i>	23		2,760,967,898	3,336,114,107
Selling expenses	25	6.5	5,501,008,993	5,842,796,323
General and administration expenses	26	6.6	15,300,786,049	14,779,741,733
Operating profit	30		575,074,350	11,777,930,928
Other income	31	6.7	171,078,925	288,357,677
Other expenses	32	6.8	-	4,310,909
Profit from other activities	40		171,078,925	284,046,768
Accounting profit before tax	50		746,153,275	12,061,977,696
Current corporate income tax expenses	51	5.13	70,942,937	1,648,174,412
Deferred corporate income tax expenses	52	5.13.1	39,662,864	411,165,034
Net profit after tax	60		635,547,474	10,002,638,250
Earning per share	70	6.10	76	1,377



**PHAM THI THU LANH**  
Preparer



**LE THI MY TIEN**  
Chief Accountant



**LE THANH TUNG**  
General Director  
Dong Thap, 11 August 2025

## TIPHARCO PHARMACEUTICAL JOINT STOCK COMPANY

Lot 08, 09 Tan My Chanh Industrial and Handicraft Cluster, My Phong Ward, Dong Thap Province, Vietnam

**INTERIM CASH FLOW STATEMENT (Indirect method)**

For the six-month period ended 30 June 2025

Currency Unit: VND

INDEX	Code Notes	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit before tax	01	746,153,275	12,061,977,696
<b>Adjustments for:</b>			
Depreciation and amortization of fixed assets, investment property	02	5,505,415,447	5,464,037,489
Provisions	03	(203,314,319)	(2,869,100,541)
Gain, loss foreign exchange rate differences upon revaluation of monetary	04	5,517,226	-
Gain, loss from investing activities	05	(12,358,995)	(35,043,942)
Interest expense	06	2,760,967,898	3,336,114,107
Others adjustments	07	-	-
<b>Operating profit before movements in working capital</b>	<b>08</b>	<b>8,802,380,532</b>	<b>17,957,984,809</b>
Increase, decrease in receivables	09	46,078,441,178	(10,665,437,998)
Increase, decrease in inventories	10	6,882,852,684	(59,581,674,769)
Increase, decrease in account payable (excluding loan interest payable and corporate income tax payable)	11	540,564,168	46,962,787,345
Increase, decrease in accrued expenses	12	133,709,182	(1,193,179,958)
Increase, decrease in trading securities	13	-	-
Interest paid	14	(2,760,967,898)	(3,336,114,107)
Corporate income tax paid	15	(3,069,372,352)	(2,249,492,075)
Other cash inflows	16	-	-
Other cash outflows	17	-	-
<b>Net cashflow used in operating activities</b>	<b>20</b>	<b>56,607,607,494</b>	<b>(12,105,126,753)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Cash outflow for purchasing and construction of fixed assets and other long-term assets	21	(364,451,000)	(15,460,928,442)
Proceeds from disposal of fixed assets and other long-term assets	22	-	25,454,545
Cash outflow for buying debt instruments of other entities	23	-	-
Cash recovered from lending, selling debt instruments of other companies	24	-	-
Investment in other entities	25	-	-
Cash recovered from investments in other entities	26	-	6,500,000,000
Interest income received, dividends received	27	12,358,995	9,589,397
<b>Net cashflow used in investing activities</b>	<b>30</b>	<b>(352,092,005)</b>	<b>(8,925,884,500)</b>

TIPHARCO PHARMACEUTICAL JOINT STOCK COMPANY

Lot 08, 09 Tan My Chanh Industrial and Handicraft Cluster, My Phong Ward, Dong Thap Province, Vietnam

**INTERIM CASH FLOW STATEMENT (Indirect method)**

For the six-month period ended 30 June 2025

Currency Unit: VND

INDEX	Code	Notes	From 01/01/2025 to 30/06/2025	From 01/01/2024 to 30/06/2024
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>				
Proceeds from issuing stocks, receiving capital from owners	31		-	-
Capital withdrawals, buying treasury shares	32		-	-
Proceeds from short-term borrowings	33	7.1	48,546,799,555	129,641,990,662
Repayment of borrowings	34	7.2	(108,058,704,676)	(112,756,000,000)
Repayment of obligations under finance leased	35		-	-
Dividends paid	36		-	(6,286,625)
<b>Net cashflow used in financing activities</b>	<b>40</b>		<b>(59,511,905,121)</b>	<b>16,879,704,037</b>
<b>Net cash inflows/ (outflows) in the period</b>	<b>50</b>		<b>(3,256,389,632)</b>	<b>(4,151,307,216)</b>
<b>Cash at beginning of the period</b>	<b>60</b>		<b>16,360,889,595</b>	<b>10,517,368,916</b>
Effects of changes in foreign exchange rate	61		632,774	-
<b>Cash at end of the period</b>	<b>70</b>	5.1	<b>13,105,132,737</b>	<b>6,366,061,700</b>



**PHAM THI THU LANH**  
Preparer



**LE THI MY TIEN**  
Chief Accountant



**LE THANH TUNG**  
General Director  
Dong Thap, 11 August 2025

## NOTES TO THE INTERIM FINANCIAL STATEMENT

For the six-month period ended 30 June 2025

These notes form an integral part of and should be read in conjunction with the accompanying interim financial statements.

### 1. GENERAL INFORMATION

#### 1.1 Ownership

Tipharco Pharmaceutical Joint Stock Company was established in Vietnam and operating under the Registration Certificate No. 1200100557, first registered on February 28, 2006, and registered for the 22nd change on July 16, 2024, issued by the Department of Planning and Investment of Dong Thap province.

The charter capital of the Company as at 30/06/2025 and 01/01/2025 is VND 83,525,730,000, equivalent to with 6,315,928 shares with par value of VND 10,000/share.

The Company's shares with stock code DTG are listed on the Hanoi Stock Exchange under Decision No. 841/QD-SGDHN dated July 24, 2024:

Type of shares	: Ordinary Share
Trading code	: DTG
Par value per share	: VND 10,000/share
Number of listed shares	: 8,352,573 shares
The total value of listed shares at par value	: VND 83,525,730,000

#### 1.2 Scope of operating activities

The Company's business sector is the production and trading of pharmaceuticals.

#### 1.3 Line of business

According to business registration Certificate, the company's business activities are:

- Real estate business, land use rights owned by the owner, user, or lessee;  
Details: Leasing land use rights, house ownership rights, and assets attached to land in cases where the State leases land; Buying, selling, leasing houses and land use rights not for residence. (excluding: not performing the activity of "investing in building infrastructure for cemeteries and graveyards to transfer land use rights attached to infrastructure").
- Warehousing and storage of goods;  
Details: Warehouses for storing ordinary goods, cold storage.
- Other professional, scientific and technological activities not elsewhere classified;  
Details: Technology transfer and technology transfer services; Product research and development services.
- Production of cosmetics, soaps, detergents, polishes, and cleaning products;  
Details: Production of cosmetics.
- Production of non-alcoholic beverages, mineral water;  
Details: Production of all kinds of soft drink syrups. Production of bottled and jarred purified water of all kinds.
- Other specialized wholesale not elsewhere classified;  
Details: Trading, importing, and exporting chemicals. (excluding: not performing distribution activities of goods that economic organizations with foreign investors are not entitled to distribute according to legal regulations at each time).
- Distilling, refining, and blending all kinds of strong alcohol;  
Details: Production of all kinds of bottled medicinal wine.
- Retailing of medicines, medical equipment, cosmetics, and hygiene products in specialized stores;  
Details: Retailing of medicines and products manufactured by the Company; Retailing of medical supplies, equipment, and medical instruments in the medical and pharmaceutical sectors; cosmetics and functional foods (excluding: not distributing goods that economic organizations with foreign investors are not allowed to distribute according to the provisions of law from time to time).



## NOTES TO THE INTERIM FINANCIAL STATEMENT

For the six-month period ended 30 June 2025

- Wholesale of beverages;

Details: Trading in bottled and jarred purified water of all kinds. Trading in soft drink syrups. Trading in bottled medicinal wines of all kinds. (excluding: not distributing goods that economic organizations with foreign investors are not allowed to distribute according to the provisions of law from time to time).

- Manufacturing of medicines, pharmaceutical chemicals, and medicinal materials;

Details: Manufacturing of medicines of all kinds. Manufacturing of pharmaceutical chemicals and medicinal materials. Manufacturing of plant products for medicinal purposes.

- Wholesale of other household appliances;

Details: Trading, importing, and exporting pharmaceuticals and medical supplies, production, and business equipment in the medical sector; Trading, importing, and exporting cosmetics; Trading, importing, and exporting medical instruments. (excluding: not performing distribution activities of goods that economic organizations with foreign investors are not entitled to distribute according to legal regulations at each time).

- Electricity production;

Details: Electricity production from solar energy.

- Electricity transmission and distribution;

Details: Electricity transmission. Electricity distribution (excluding: not performing transmission activities, regulating the National Power System).

- Manufacturing medical, dental, orthopedic, and rehabilitation equipment and instruments;

Details: Manufacturing medical equipment and instruments.

- Activities of general, specialized, and dental clinics;

Details: Activities of general and specialized clinics.

- Production of vaccines, biological products, cosmetics, preparations, and packaging. Trading, importing, and exporting raw materials. Trading, importing, and exporting vaccines, biological products, preparations, and packaging. Processing, franchising in the production and business of pharmaceuticals, medical supplies, functional foods, vaccines, biological products, cosmetics, preparations, raw materials, chemicals, packaging, production, and business equipment in the medical sector. Production, trading, export, and import of functional foods. Production of essential oils from herbs. (except: not performing distribution activities of goods that economic organizations with foreign investors are not entitled to distribute according to legal regulations at each time).

During the period, the Company's main activities are as follows: Manufacturing of pharmaceuticals, chemicals, and medicinal materials, details: manufacturing of pharmaceuticals; manufacturing of chemicals and medicinal materials; manufacturing of plant products for medicinal purposes.

### 1.4 Business cycle

Business cycle of the Company is not exceeding 12 months.

### 1.5 Reclaim comparative information in financial statements

Figures which are presented in Financial statements for the financial period ended 30 June 2025 can be compared with the last period corresponding figures.

### 1.6 The number of the employees and employer

As at 30 June 2025, the Company has 259 people (31 December 2024: 265 people).

## NOTES TO THE INTERIM FINANCIAL STATEMENT

For the six-month period ended 30 June 2025

---

### 2. ACCOUNTING PERIOD AND ACCOUNTING CURRENCY

#### 2.1 Fiscal year

The fiscal year of the Company is from January 01 to December 31 annually.

#### 2.2 Currency unit in Financial Statements

The Company maintains its accounting records in Vietnamese dong (VND) due to the collect and spending made primarily by currency VND.

### 3. APPLICABLE ACCOUNTING STANDARDS AND REGIME

#### 3.1 Applicable Accounting Standards and Regime

The Company complied with the Vietnamese accounting standards, Vietnamese Enterprises accounting systems guided on the Circular No. 200/2014/TT-BTC dated 22 December 2014 and the Circular No. 53/2016/TT-BTC dated 21 March 2016 and Circulars guiding to perform accounting standards of the Ministry of Finance in interim Financial Statements preparation.

#### 3.2 Comply with the Vietnamese Accounting Standards and Vietnamese Accounting Regime

The Board of General Directors ensures to obey requirements of accounting standards, Vietnamese Enterprises accounting systems issued based on the Circular No. 200/2014/TT-BTC dated 22 December 2014 and the Circular No. 53/2016/TT-BTC dated 21 March 2016 as well as Circulars guiding to perform accounting standards of the Ministry of Finance in interim Financial Statements preparation.

### 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### 4.1 Basis of preparation the financial statements

The financial statements are prepared on the accrual basis (except for information relating to cash flows).

#### 4.2 Cash and cash equivalents

Cash comprises cash on hand, cash in banks (demand deposits) and cash in transit. Cash equivalents are short-term highly liquid investments with an original maturity of three months or less from the date of investment, which are readily convertible into known amounts of cash and which are subject to an insignificant risk of change in value at the report date.

#### 4.3 Receivables

Trade and other receivables are stated at cost less provision for doubtful debts. The classification of receivables are trade receivables and other receivables, which complied with the following principles:

- Trade receivables reflect the nature of the receivables arising from commercial transactions with purchase - sale between the Company and an independent purchaser.
- Other receivables reflect the nature of the receivables arising from non-commercial transactions, and to be related to the purchase – sale transactions.

The provision for doubtful debts represents the estimated loss due to non-payment arising on receivables that were outstanding at the balance sheet date.

Increases and decreases to the provision balance are recognised as general and administration expenses in the income statement.

## NOTES TO THE INTERIM FINANCIAL STATEMENT

For the six-month period ended 30 June 2025

### 4.4 Inventories

Inventories are presented at the lower of cost and net realizable value.

The cost of inventories is determined as follows:

- Materials and goods: comprising all costs of purchase and related expenses directly incurred in bringing the inventories to their present location and condition.
- Work-in-progress: include the cost of raw materials, direct labor cost and production overhead, land use right cost and directly related costs incurred in construction process.
- Finished goods: including the cost of materials, direct labour and general manufacturing costs related to allocate on normal levels.

Net realizable value represents the estimated selling price of inventory during the normal production and business minus the estimated costs to completion and the estimated costs necessary to consume them.

The Company applies the perpetual inventory method of accounting for inventories and the cost is determined on the weighted average method.

Provision for impairment of inventories is made for each inventory with the cost greater than the net value realizable. For service in progress, the provision for impairment is calculated for each type of service has a separate price. Increase or decrease in the balance of provision for impairment of inventories should be set aside at the fiscal period end and is recognized in cost of goods sold.

### 4.5 Prepaid expenses

Prepaid expenses is used to record expenses actually incurred but they are related to operation output of many accounting period. Prepaid expenses include:

#### *Tools and equipment*

The tools and equipment have been put into use and are amortized to expense under the straight-line method to time allocation in 36 months.

#### *Prepaid land rental*

Prepaid land rental represents an amount paid for the land which the company is using. Prepaid land rental is amortized on a straight-line basis to the lease term respectively over the lease term of 472 months.

#### *Long-term prepaid expenses*

Other long-term prepaid expenses incurred once with large value are allocated to expenses using the straight-line method with an allocation period of no more than 36 months.

### 4.6 Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation.

The initial cost of a tangible fixed asset comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures for additions, improvements and renewals are capitalised on fixed assets accounts, expenditures for maintenance and repairs are charged to the income statement.

When assets are sold or retired, their cost and accumulated depreciation are removed from the balance sheet and any gain or loss resulting from their disposal is included in the income statement. Depreciation of tangible fixed assets is calculated on a straight-line basis over the estimated useful life of these assets.

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

Depreciation of tangible fixed assets such as:

	Time
Building, structures	6 - 50 years
Machinery and equipment	2 - 15 years
Transportation	5 - 25 years

**4.7 Intangible fixed assets**

Intangible fixed assets are stated at cost less accumulated depreciation.

The initial cost of an intangible fixed asset comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures for additions, improvements and renewals are capitalised on fixed assets accounts, expenditures for maintenance and repairs are charged to the income statement.

When assets are sold or retired, their cost and accumulated depreciation are removed from the balance sheet and any gain or loss resulting from their disposal is included in the income statement.

Intangible fixed assets include:

***Land use rights***

The land use right reflects all the actual expenses related to the used land such as expenses to obtain the land use right, expenses for house removal and land clearance, expenses on ground levelling, registration fees, etc.

The Company's land use rights are amortized as follows: amortized using the straight-line method over the land use term (indefinite land use rights are not amortized).

**4.8 Construction in progress**

Construction in progress presents costs directly related to (including interest expenses suitable for relevant accounting policies of the Company) fixed assets are constructing, equipment, machines are installing for production, leasing and management as well as the cost of unfinished construction. These assets are initially recognized at cost and not amortized.

**4.9 Accounts payable and accrued expense payables**

Accounts payable and accrued expenses are recognized for amounts to be paid in the future, which related to receive the goods and services. Accrued expenses are recorded based on reasonable estimates payment.

The classification of liabilities is payable to suppliers, accrued expenses and other payables, which complied with the following principles:

- Trade payable reflects the nature of the payables arising from commercial transactions with purchase of goods, services, property between the Company and independent sellers.
- Accrued expenses reflect the payables for goods and services received from the seller or provided with the purchaser but have not been paid until having invoices or having insufficient billing records, accounting records, and production costs, sales must accruals.
- Other payables reflects the nature of the payables of non-commercial, not related to the purchase, sale, rendering service transactions.



## NOTES TO THE INTERIM FINANCIAL STATEMENT

For the six-month period ended 30 June 2025

---

### 4.10 Owner's equity

Capital is recorded according to the amount actually invested by shareholders.

### 4.11 Distribution of net profits

Profit after tax is distributed to shareholders after an appropriation of funds under the Charter of the Company as same as the law and is approved by the General Meeting of Shareholders.

The distribution of profits to shareholders is considered to non-cash items in undistributed profit may affect cash flow and ability to pay dividends as profit from revaluation of assets contributed as capital, interest due to the revaluation of monetary items, the financial instruments and other non-cash items.

Dividends are recognized as liabilities when approved by the General Meeting of Shareholders.

### 4.12 Revenue

#### *Revenue from sale of goods*

Sale of goods shall be recognized if it simultaneously meets the following conditions:

- The company has transferred the majority of risks and benefits associated with the right to own the products or goods to the buyer;
- The company no longer holds the right to manage the goods as the goods owner, or the right to control the goods;
- Turnover has been determined with relative certainty;
- The company has gained or will gain economic benefits from the good sale transaction;
- It is possible to determine the costs related to the goods sale transaction.

#### *Revenue from rendering of service*

Revenue of a transaction involving the rendering of services is recognised when the outcome of such transactions can be measured reliably. In case that a transaction involves the rendering of services is attributable to several periods, revenue is recognised in each period by reference to the percentage of completion of the transaction at the interim balance sheet date of that period. The outcome of a transaction can be measured reliably when all four (4) following conditions are satisfied:

- The amount of revenue can be measured reliably;
- It is probable that the economic benefits associated with the transaction will flow to the company;
- The percentage of completion of the transaction at the balance sheet date can be measured reliably;
- The costs incurred for the transaction and the costs to complete the transaction can be measured reliably.

#### *Interest*

Interest is recognized on an accrual basis, are determined on the balance of cash in bank and the actual interest rate for each period.

### 4.13 Borrowing costs

Borrowing costs include interest and other costs incurred directly related to the borrowings.

Borrowings costs are recognized as expenses when incurred.



## NOTES TO THE INTERIM FINANCIAL STATEMENT

For the six-month period ended 30 June 2025

### 4.14 Corporate income tax

#### *Current income tax*

Current income tax is the tax amount is calculated on taxable income. Taxable income is different from accounting profit due to the adjustments of temporary differences between accounting and tax, non-deductible expenses as well as adjusted income are not taxed and losses be transferred.

#### *Deferred income tax*

Deferred income tax is the corporate income tax will pay or will be refunded by the temporary differences between the carrying amounts of assets and liabilities for the purpose of preparing the financial statements and the basis to calculate income tax. Deferred income tax is recognized for all temporary differences tax. Deferred tax assets are only recognized when the certainty of future get the taxable profits to use those temporary deductible differences.

The carrying amount of deferred tax assets are reconsidered at closing of the financial period and will be reversed to make sure that there is enough taxable profit to allow the benefit assets to be used fully or partly. The deferred tax assets were not previously recognized is reconsidered at closing of the financial period and is recognized when it is sure to enough taxable profit to be able to use this deferred tax assets.

Deferred tax assets and deferred income tax payable is calculated at the estimated tax rates that is applied in the asset is realized or the liability is settled in accordance with the tax rates in effect at closing fiscal period. Deferred income tax is recognized in the income statement and record directly to equity when the tax relates to items directly to equity.

Deferred tax assets and deferred income tax payables are off set as follows:

- The company has a legal right to offset between current income tax assets and current income taxes payable; and
- Deferred tax assets and and deferred income tax payables are related to corporate income tax is administered by the same tax authority;
  - + For the same taxable company; or
  - + The Company intends to pay current income taxes and deferred tax assets on the basis of net assets or recovered asset at the same with the payment of liabilities for each of periods in future when the materiality of deferred income tax or deferred tax assets to be paid or recovered.

Tax settlement of the Company and its subsidiaries will be assessed by the Tax Department. Due to the application of laws and regulations on taxes for different incurred transactions which can be explained in many different ways, tax payable presented in the financial statements can be immediately changed according to the decision of the tax authorities.

### 4.15 Segment report

Segment by business sector is a part determined separately participate in the process of producing or providing products, services, risks and other economic benefits business with parts other.

Segment by geographical area is a part determined separately participate in the process of producing or providing products, services within a specific economic environment and risks and economic benefits different to business part in other economic environments.

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**4.16 Financial instruments****Financial assets**

The classification of financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Financial assets of the Company include cash and cash equivalents, customer receivables and other receivables.

At the time of initial recognition, financial assets are determined at cost plus any costs directly acquisition, issuance of such financial assets.

At the time of initial recognition, except for financial hire-purchase-related liabilities and convertible bonds recorded at the allocation value, other financial liabilities initially recorded at the original price minus transaction expenses directly related to such financial liabilities.

Amortized cost of a financial asset or financial liability is determined as equaling the initially recognized value of that financial asset or financial liability minus principals, plus or minus accrued amortizations calculated by the effective interest method of the difference between the initially recorded value and the value upon maturity, minus deductions (directly or through a contingency account) due to impairment or irrecoverability. Actual interest method is a method of calculating the amortized cost of one or a group of financial assets or financial liabilities and distributing profit incomes or expenses in the associated period. Effective interest rate is discount interest rate of cash flows forecast to be settled or obtained in the future throughout the expected life cycle of a financial instrument or in a shorter period, when necessary, to return to the current net carrying amount of a financial asset or financial liability.

**Equity instruments**

Equity instrument is a contract that proves the remaining interests in the Company's assets after offsetting all obligations.

**Offsetting of financial instruments**

The financial assets and financial liabilities are offset and the net amount is presented on the balance sheet, if and only if:

- The Company has the legal right to offset the values were recognized;
- The Company has to offset on a basis, or to realize the asset and pay the liability simultaneously.

**4.17 Related parties**

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if one party is controlled by, or are under common control with the Company.

In considering relationship among related parties, the nature of relationship is more important than that of formality. The following parties are known as the Company's related parties:

<b>Companies' name</b>	<b>Relationship</b>
AAA Assurance Corporation	Co-managed by key personnel
Tam sinh nghĩa investment development joint stock company	Co-managed by key personnel
Magnolia Investment Corporation	Co-managed by key personnel
Members of Board of Management, Board of Supervisors, Board of General Directors and Chief Accountant	Key members

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**5. ADDITIONAL INFORMATION TO ITEMS IN INTERIM BALANCE SHEET****5.1 Cash and cash equivalents**

	30/06/2025 VND	01/01/2025 VND
Cash on hand - VND	2,627,085,078	247,299,879
Cash at banks		
+ VND	10,470,995,332	16,106,367,736
+ USD (*)	7,052,327	7,221,980
	<b>13,105,132,737</b>	<b>16,360,889,595</b>

(\*) Detail of balance of cash in foreign currency as at 30 June 2025 is as follows:

	Original currency	Equivalent to VND
Cash at banks		
+ USD	272.08	7,052,327
		<b>7,052,327</b>

**5.2 Short-term trade receivables**

	30/06/2025 VND	01/01/2025 VND
<b>Trade receivables – the related parties</b>		
Tam sinh nghĩa investment development joint stock company	19,344,365	-
<b>Trade receivables – other customers</b>		
Pegasus Pharmaceutical Company, Limited	12,722,277,630	27,704,660,490
Other customers	49,794,029,338	80,170,796,923
	<b>62,535,651,333</b>	<b>107,875,457,413</b>

**5.3 Short-term advances to suppliers**

	30/06/2025 VND	01/01/2025 VND
<b>Advances to suppliers – other suppliers</b>		
Roshn Technology New Material (ZhengYang) Co., Ltd	-	500,799,600
VN TND Technology Corporation	-	188,853,770
Ho Chi Minh City Institute Of Drug Testing	-	306,500,000
Saticus Science And Technology Co.,Ltd	104,720,000	206,937,500
SBS Securities Joint Stock Company	125,000,000	125,000,000
FPT Securities Joint Stock Company - Ho Chi Minh Branch	44,000,000	-
Other suppliers (*)	93,778,900	156,650,000
	<b>367,498,900</b>	<b>1,484,740,870</b>

(\*) In which, the whole currency is USD 350.00 equivalent to VND 9,131,500.

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**5.4 Other short-term, long-term receivables****5.4.1 Other short-term receivables**

	30/06/2025		01/01/2025	
	Amount VND	Provision VND	Amount VND	Provision VND
<b>Other receivables - other individual, organizations</b>				
Mr. Nguyen Hoang Viet - Advance	290,787,891	-	-	-
Other parties - Other receivables	209,902,917	-	98,575,456	-
	<b>500,690,808</b>	<b>-</b>	<b>98,575,456</b>	<b>-</b>

**5.4.2 Other long-term receivables**

	30/06/2025		01/01/2025	
	Amount VND	Provision VND	Amount VND	Provision VND
<b>Other receivables – related parties</b>				
Magnolia Investment Corporation - Deposits	305,145,000	-	305,145,000	-
<b>Other receivables</b>				
Other parties - Other receivables	750,000	-	750,000	-
	<b>305,895,000</b>	<b>-</b>	<b>305,895,000</b>	<b>-</b>

**5.5 Bad debts**

	30/06/2025		01/01/2025	
	Cost VND	Recoverable amount VND	Cost VND	Recoverable amount VND
Trade receivables	3,648,324,943	2,257,700,944	2,330,470,000	1,376,059,124
	<b>3,648,324,943</b>	<b>2,257,700,944</b>	<b>2,330,470,000</b>	<b>1,376,059,124</b>

Movements of provision for doubtful debts are as follow:

	Trade receivables VND
As at 01/01/2025	(954,410,876)
Provision for doubtful debt	(436,213,123)
Debt write-off during the period	-
<b>As at 30/06/2025</b>	<b>(1,390,623,999)</b>

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**5.6 Inventories**

	<b>30/06/2025</b>		<b>01/01/2025</b>	
	<b>Cost</b>	<b>Provision</b>	<b>Cost</b>	<b>Provision</b>
	<b>VND</b>	<b>VND</b>	<b>VND</b>	<b>VND</b>
Raw materials	27,944,967,196	(211,750,709)	36,511,980,260	(423,660,958)
Work in progress	5,938,377,858	-	2,880,022,521	-
Finished goods	63,373,928,175	-	64,183,690,406	(370,433,860)
Goods	113,852,300	-	425,020,300	-
Goods on consignment	990,858,078	-	1,244,122,804	-
	<b>98,361,983,607</b>	<b>(211,750,709)</b>	<b>105,244,836,291</b>	<b>(794,094,818)</b>

**5.7 Short-term, long-term prepaid expenses****5.7.1 Short-term prepaid expenses**

	<b>30/06/2025</b>	<b>01/01/2025</b>
	<b>VND</b>	<b>VND</b>
Fire insurance expenses	182,912,805	27,541,693
Software	280,280,000	112,922,690
Others	14,797,500	44,392,500
	<b>477,990,305</b>	<b>184,856,883</b>

**5.7.2 Long-term prepaid expenses**

	<b>30/06/2025</b>	<b>01/01/2025</b>
	<b>VND</b>	<b>VND</b>
Repair assets expenses	523,671,112	1,591,572,762
Land lease expense	6,394,113,930	6,491,733,990
Others	1,552,386,591	813,707,485
	<b>8,470,171,633</b>	<b>8,897,014,237</b>



**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**5.8 Increase/ (decrease) of tangible fixed assets**

	Building, structures VND	Machinery and equipment VND	Transportation VND	Total VND
<b>Cost</b>				
As at 01/01/2025	52,603,724,573	97,143,087,271	52,427,327,138	202,174,138,982
Purchase in period	-	358,750,000	246,901,000	605,651,000
As at 30/06/2025	52,603,724,573	97,501,837,271	52,674,228,138	<b>202,779,789,982</b>
<b>Accumulated depreciation</b>				
As at 01/01/2025	13,744,456,900	69,755,065,636	21,697,784,687	105,197,307,223
Depreciation in period	717,989,190	3,035,305,069	1,752,121,188	5,505,415,447
As at 30/06/2025	14,462,446,090	72,790,370,705	23,449,905,875	<b>110,702,722,670</b>
<b>Net book value</b>				
As at 01/01/2025	38,859,267,673	27,388,021,635	30,729,542,451	96,976,831,759
As at 30/06/2025	38,141,278,483	24,711,466,566	29,224,322,263	<b>92,077,067,312</b>

Cost of fixed tangible assets which are fully depreciated but still in use:

As at 01/01/2025	773,236,081	37,443,566,878	9,920,560,088	48,137,363,047
As at 30/06/2025	773,236,081	41,377,141,878	9,920,560,088	<b>52,070,938,047</b>

Net book value of tangible fixed assets which are mortgaged at banks to guarantee borrowings:

As at 01/01/2025	32,337,909,976	11,509,780,311	14,369,019,527	58,216,709,814
As at 30/06/2025	31,765,153,486	10,326,351,615	13,534,147,589	<b>55,625,652,690</b>

**5.9 Increase/ (decrease) of intangible fixed assets**

	Land use rights VND
<b>Cost</b>	
As at 01/01/2025	550,000,000
As at 30/06/2025	<b>550,000,000</b>
<b>Accumulated depreciation</b>	
As at 01/01/2025	-
As at 30/06/2025	-
<b>Net book value</b>	
As at 01/01/2025	550,000,000
As at 30/06/2025	<b>550,000,000</b>

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**5.10 Deferred income tax assets**

	01/01/2025	Reversal in period	30/06/2025
	VND	VND	VND
Deferred tax assets related to temporary deductible differences	599,202,805	(39,662,864)	559,539,941
	<b>599,202,805</b>	<b>(39,662,864)</b>	<b>559,539,941</b>

**5.11 Trade accounts payable**

	Original currency USD	30/06/2025 VND	01/01/2025 VND
<b>Accounts payables to suppliers - related parties</b>			
Magnolia Investment Corporation		378,921,896	-
<b>Accounts payables to other suppliers</b>			
2B Trading And Service Co.,Ltd		2,973,575,871	-
Sinopharm Weiqida Pharmaceutical Co.,Ltd	123,000.00	3,231,210,000	-
Multipack Company Limited		2,956,288,995	2,081,751,705
Phuc Dan International Pharmaceutical Trading Corporation		3,429,083,507	3,800,767,442
Other suppliers		11,019,886,871	13,094,304,238
		<b>23,988,967,140</b>	<b>18,976,823,385</b>

**5.12 Short-term advance from customers**

	30/06/2025 VND	01/01/2025 VND
<b>Advance from other customers</b>		
Vian Pharmaceutical Joint Stock Company	-	569,624,235
Hiep Thuan Thanh Medical Company Limited	633,322,009	624,063,856
An Pha Pharma Trading Company Limited	138,752,190	1,434,219,458
Vu Duy Pharmaceutical Joint Stock Company	435,733,312	435,733,312
Villamed Joint Stock Company	527,158,070	257,603,670
Gspharm Joint Stock Company	534,050,295	524,469,045
Other customers (*)	1,939,257,355	1,602,909,939
	<b>4,208,273,231</b>	<b>5,448,623,515</b>

(\*) In which, the whole currency is USD 2,799.00 equivalent to VND 65,608,560.

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**5.13 Tax and other receivables/ payables to the State Budget**

	01/01/2025		Movement in the period		30/06/2025	
	Taxes Payable VND	Taxes Receivable VND	Payables VND	Paid VND	Taxes Payable VND	Taxes Receivable VND
Value added tax on domestic goods	1,733,467,186	-	874,234,550	(1,733,467,185)	874,234,551	-
Value added tax on imports	-	-	2,487,851,460	(2,487,851,460)	-	-
Corporate income tax	2,982,275,031	-	70,942,937	(3,069,372,352)	-	(16,154,384)
Personal income tax	130,702,279	-	729,944,669	(754,973,389)	105,673,559	-
Land and housing taxes	-	-	163,414,390	(163,414,390)	-	-
Other taxes	-	-	7,000,000	(7,000,000)	-	-
	<b>4,846,444,496</b>	<b>-</b>	<b>4,333,388,006</b>	<b>(8,216,078,776)</b>	<b>979,908,110</b>	<b>(16,154,384)</b>

## Value added Tax:

The Company paid value added tax payable under deduction. Value added tax rate was 5%, 8% and 10%.

## Corporate income tax:

The Company is obliged to pay corporate income tax for taxable income at the rate of 20%.

The company is exempt for 4 years and receives a 50% reduction in tax payable for the following 9 years for income from production and business activities involving products formed from scientific and technological results.

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

Corporate income tax ("CIT") payable for the period is estimated as follows:

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Accounting profit before tax	746,153,275	12,061,977,696
Adjustments to increase, decrease accounting profit before tax to determine income:		
- Adjustments to increase	541,213,123	416,355,585
- Adjustments to decrease	(739,527,442)	(2,055,825,170)
<b>Taxable income</b>	<b>547,838,956</b>	<b>10,422,508,111</b>
- Tax-incentive income	386,248,544	4,363,272,103
- Non-tax-incentive income	161,590,412	6,059,236,008
Corporate income tax rate		
- Preferential tax rate	10%	10%
- Ordinary tax rate	20%	20%
<b>Total corporate income tax payable</b>	<b>70,942,937</b>	<b>1,648,174,412</b>

**5.13.1 Deferred corporate income tax expenses**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Deferred corporate income tax expense charge from reversal of deferred tax assets	39,662,864	411,165,034
	<b>39,662,864</b>	<b>411,165,034</b>

**5.14 Short-term accrued expenses**

	30/06/2025 VND	01/01/2025 VND
Advance payment of remuneration for the Board of Management	525,000,000	420,000,000
Other accrued expenses	46,138,947	483,909,836
	<b>571,138,947</b>	<b>903,909,836</b>

**5.15 Other short-term payables**

	30/06/2025 VND	01/01/2025 VND
<b>Other payables - other organizations and individuals</b>		
Circa Pharmacy Co., Ltd - deposit	1,200,000,000	1,200,000,000
Nam Hung Pharmaceutical Service Trading Co., Ltd - deposit	400,000,000	400,000,000
Hoa Phat Pharmaceutical Joint Stock Company - deposit	435,000,000	-
Windi Pharmaceutical Company Limited - deposit	500,000,000	-
Hung Thinh International Pharmaceutical Trading Co., Ltd - deposit	303,046,290	303,046,290
Other payables	1,117,996,510	868,249,310
	<b>3,956,042,800</b>	<b>2,771,295,600</b>

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**5.16 Short-term loans and finance lease liabilities**

	30/06/2025		01/01/2025	
	Carrying amount	Amount within repayment capacity	Carrying amount	Amount within repayment capacity
	VND	VND	VND	VND
<b>Short-term loan - other organizations and individuals</b>				
Joint stock Commercial Bank for Investment and Development of Viet Nam	51,780,787,055	51,780,787,055	111,292,692,176	111,292,692,176
	<b>51,780,787,055</b>	<b>51,780,787,055</b>	<b>111,292,692,176</b>	<b>111,292,692,176</b>

This is a loan from Vietnam Joint Stock Commercial Bank for Investment and Development under Contract No. 01/2024/433498/HDTD, with a total loan limit of VND 120,000,000,000, loan term from 5 to 6.5 months, the purpose of the loan is to supplement working capital for production and business activities, with a loan term of 12 months, interest rate until June 30, 2025 from 6%/year to 6.6%/year, the unit's fixed assets secure this loan, the balance as of June 30, 2025 is VND 51,780,787,055.

Detail of short-term loan transaction in period is as follow:

	01/01/2025	Incurring in period	Paid in period	30/06/2025
	VND	VND	VND	VND
Joint stock Commercial Bank for Investment and Development of Viet Nam	111,292,692,176	48,546,799,555	(108,058,704,676)	51,780,787,055
	<b>111,292,692,176</b>	<b>48,546,799,555</b>	<b>(108,058,704,676)</b>	<b>51,780,787,055</b>

**5.17 Bonus and welfare funds**

	01/01/2025	Fund appropriation during the period	Used in period	30/06/2025
	VND	VND	VND	VND
Welfare fund	259,944,653	-	-	259,944,653
	<b>259,944,653</b>	<b>-</b>	<b>-</b>	<b>259,944,653</b>

**5.18 Provision for long-term payables**

	30/06/2025	01/01/2025
	VND	VND
<b>Payables from other entities and individuals</b>		
Provision for severance allowances	670,325,000	727,508,333
	<b>670,325,000</b>	<b>727,508,333</b>



**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**5.19 Owners' equity****5.19.1 The table of equity fluctuation**

	Owner's invested capital	Capital Surplus	Investment and development funds	Retained earnings	Total
	VND	VND	VND	VND	VND
As at 01/01/2024	72,632,100,000	33,634,115,000	19,313,275,717	37,341,228,584	162,920,719,301
Profit in period	-	-	-	10,002,638,250	10,002,638,250
As at 30/06/2024	<b>72,632,100,000</b>	<b>33,634,115,000</b>	<b>19,313,275,717</b>	<b>47,343,866,834</b>	<b>172,923,357,551</b>
As at 01/07/2024	72,632,100,000	33,634,115,000	19,313,275,717	47,343,866,834	172,923,357,551
Profit in period	-	-	-	13,134,705,555	13,134,705,555
Dividends paid	10,893,630,000	-	-	(10,893,630,000)	-
As at 31/12/2024	<b>83,525,730,000</b>	<b>33,634,115,000</b>	<b>19,313,275,717</b>	<b>49,584,942,389</b>	<b>186,058,063,106</b>
As at 01/01/2025	83,525,730,000	33,634,115,000	19,313,275,717	49,584,942,389	186,058,063,106
Profit in period	-	-	-	635,547,474	635,547,474
As at 30/06/2025	<b>83,525,730,000</b>	<b>33,634,115,000</b>	<b>19,313,275,717</b>	<b>50,220,489,863</b>	<b>186,693,610,580</b>

**5.19.2 Detail of owners' invested capital**

Shareholders	30/06/2025			01/01/2025		
	Shares	VND	Rate	Shares	VND	Rate
Mr. Nguyen Ho Nam	2,076,325	20,763,250,000	24.86%	2,076,325	20,763,250,000	24.86%
Ms. Dang Thi Thu Hang	2,038,568	20,385,680,000	24.41%	2,038,568	20,385,680,000	24.41%
Bamboo Capital Group Joint Stock Company	1,754,957	17,549,570,000	21.01%	1,754,957	17,549,570,000	21.01%
Ms. Nguyen Phuong Hoa	941,296	9,412,960,000	11.27%	941,296	9,412,960,000	11.27%
Magnolia Investment Corporation	431,100	4,311,000,000	5.16%	431,100	4,311,000,000	5.16%
Other shareholders	1,110,327	11,103,270,000	13.29%	1,110,327	11,103,270,000	13.29%
	<b>8,352,573</b>	<b>83,525,730,000</b>	<b>100%</b>	<b>8,352,573</b>	<b>83,525,730,000</b>	<b>100%</b>

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**5.19.3 Shares**

	30/06/2025	01/01/2025
Registered number of issued shares	8,352,573	8,352,573
Number of shares sold to the public		
- Ordinary shares	8,352,573	8,352,573
- Preferred shares	-	-
	<b>8,352,573</b>	<b>8,352,573</b>
Number of repurchased shares		
- Ordinary shares	-	-
- Preferred shares	-	-
	-	-
Number of shares in circulation		
- Ordinary shares	8,352,573	8,352,573
- Preferred shares	-	-
	<b>8,352,573</b>	<b>8,352,573</b>

Ordinary share's face value is VND 10,000/share.

**5.20 Off-Statement of interim financial position accounts****Foreign currencies**

	30/06/2025	01/01/2025
U.S Dollar (USD)	272.08	285.28
	<b>272.08</b>	<b>285.28</b>

**Precious metals, gemstones**

	30/06/2025		01/01/2025	
	Quantity (mace)	VND	Quantity (mace)	VND
Gold ring 24K	14	73,760,000	72	382,580,000
	<b>14</b>	<b>73,760,000</b>	<b>72</b>	<b>382,580,000</b>

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**6. ADDITIONAL INFORMATION TO ITEMS IN THE INTERIM INCOME STATEMENT****6.1 Revenue from sales of goods and services rendered****6.1.1 Revenues total**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
<b>Revenues total</b>	<b>127,536,442,904</b>	<b>150,458,863,097</b>
<i>In which:</i>		
Revenue from sale of goods	419,400,000	3,364,393,636
Revenue from sales of finished products	127,023,399,412	146,988,813,825
Revenue from rendering services	93,643,492	105,655,636
<b>Revenue deductions</b>	<b>3,288,449,011</b>	<b>769,018,515</b>
<i>In which:</i>		
Trade discounts	3,022,117,811	215,350,115
Sale returns	266,331,200	553,668,400
<b>Net revenue</b>	<b>124,247,993,893</b>	<b>149,689,844,582</b>

**6.1.2 Revenues from sales and services rendered with the related parties**

Transactions of trading and supplying service for related parties are presented at Notes 9.2.

**6.2 Cost of goods sold**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Cost of merchandise sold	371,070,000	3,069,805,169
Cost of finished products sold	100,328,046,091	114,208,879,632
Reversal of inventory write-down provision	(582,344,109)	(2,374,245,925)
	<b>100,116,771,982</b>	<b>114,904,438,876</b>

**6.3 Financial income**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Interest on term deposits	12,358,995	9,589,397
Interest on foreign exchange differences	167,310,882	16,515,445
	<b>179,669,877</b>	<b>26,104,842</b>

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**6.4 Financial expenses**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Interest expenses	2,760,967,898	3,336,114,107
Foreign exchange losses	104,486,781	358,631,399
Payment discounts	68,567,717	-
Reversal of provision for investment losses	-	(1,283,703,942)
	<b>2,934,022,396</b>	<b>2,411,041,564</b>

**6.5 Selling expenses**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Staff cost	3,445,168,500	3,882,492,147
Outside services rendered	1,136,898,351	815,543,706
Depreciation cost	102,728,772	102,728,772
Taxes and fees	40,450,586	16,722,550
Others	775,762,784	1,025,309,148
	<b>5,501,008,993</b>	<b>5,842,796,323</b>

**6.6 General and administration expenses**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Staff cost	6,203,178,622	7,647,768,801
Outside services rendered	6,998,588,164	4,691,715,404
Provision for bad debts	436,213,123	788,849,326
Depreciation cost	251,773,704	258,202,974
Others	1,411,032,436	1,393,205,228
	<b>15,300,786,049</b>	<b>14,779,741,733</b>

**6.7 Other income**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Profit on sales of fixed assets	-	25,454,545
In which:		
- Proceeds from disposal of fixed assets	-	25,454,545
- Net book value for disposal of fixed assets	-	-
Other income	171,078,925	262,903,132
	<b>171,078,925</b>	<b>288,357,677</b>

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**6.8 Other expenses**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Other expenses	-	4,310,909
	-	<b>4,310,909</b>

**6.9 Production cost according to factors**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Cost of raw materials	83,132,044,203	134,801,405,822
Staff cost	18,981,073,646	21,924,219,686
Depreciation cost	5,505,415,447	5,464,037,489
Outside services rendered	12,651,417,859	10,366,772,508
Other cost	2,663,458,929	3,224,486,252
	<b>122,933,410,084</b>	<b>175,780,921,757</b>

**6.10 Earning per share**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Income after tax	635,547,474	10,002,638,250
The adjusted increase of accounting profit to determine profit attributable to shareholders holding ordinary shares:		
Setting up bonus and welfare fund	-	-
Profit allocated to shareholders owning ordinary shares	635,547,474	10,002,638,250
Weighted average number of ordinary shares circulating during the period (share)	8,352,573	7,263,210
<b>Basic earnings per share (VND/share)</b>	<b>76</b>	<b>1,377</b>

**7. ADDITIONAL INFORMATION TO ITEMS IN THE INTERIM CASH FLOW****7.1 Proceeds from loans**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Proceeds from borrowings under normal contract	48,546,799,555	129,641,990,662

**7.2 Repayment of borrowings**

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Cash repayment of loans from borrowings under normal contract	108,058,704,676	112,756,000,000



## NOTES TO THE INTERIM FINANCIAL STATEMENT

For the six-month period ended 30 June 2025

---

### 8. FINANCIAL INSTRUMENTS

The Company may have financial assets such as trade receivables and other receivables, Other long-term investments cash and short-term deposits that arise directly from the operations of the company. Financial liabilities of the Company mainly consist of loans, trade payables and other payables. The main purpose of these financial liabilities is to gather the financial resources to serve the activities of the Company.

The company incurs from market risk, credit risk and liquidity risk.

Operational risk management is indispensable operations for the entire business operations of the Company. The company has developed control system to ensure balance at a reasonable level between the costs when incurred risk and risk management costs.

Board of General Directors considered and uniformly applied policies to manage each of these risks are summarized below:

#### i Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk has four types of risk: interest rate risk, currency risk, goods price risk and other price risk, such as share price risk.

##### *Interest rate risk*

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Market risk for changes in interest rates of the Company primarily correlates to cash, short term deposits, bonds, and loans of the Company.

The company manages interest rate risk by analyzing the competitive situation in the market to acquire beneficial interest for company's purposes, but still remain within the limits of their risk management.

##### *Foreign currency risk*

The company bears the risk of exchange rate due to fluctuation in fair value of future cash flows of a financial instrument according to changes in exchange rates. The Company is exposed to the risk of exchange rate changes directly related to its business operations.

The company has foreign exchange risk from the purchase, sale and borrowings denominated in other currencies, which are different from the accounting currency of the Company. The company manages foreign currency risk by considering the current market situation and expected when the company plans to buy and sell in foreign currency in the future.

##### *Credit risk*

Credit risk is the risk that one party of a financial instrument or contract not performing its obligations, resulting in financial losses. The Company has credit risk from its operating activities (primarily for trade receivables account), and from its financial activities, including bank deposits, foreign exchange transactions and the other financial instruments.

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**Trade receivables**

The company regularly keeps track of the receivables, which is not yet collected. For big customers, the Company considered the decline in the credit quality of each customer at the reporting date. The company seeks the way to remained the tight control of the receivables and arranging credit control staff to minimize credit risk. On this basis and the trade receivables of the Company related to various customers, credit risk is not significantly concentrated in a certain customer.

**Cash in bank**

The company mainly maintained deposit balances at wel-known banks in Vietnam. Credit risk of the deposit balances at banks is managed by the treasury department of the Company the company's policies. The maximum credit risk of the Company for the items on the interim balance sheet at the end of the financial period is the value book presented in Notes 5.1. The company found that the level of concentration of credit risk on bank deposits is low.

**ii Liquidity risk**

Liquidity risk is the risk that the Company will encounter difficulties in implementing their financial obligations due to lack of funds. Liquidity risk of the company mainly arises from maturity mismatches of financial assets and financial liabilities.

Company minimizes the liquidity risk by maintaining an amount of cash and cash equivalents and bank loans at a level that the Board of General Directors believes it is sufficient to meet the company's operations and minimize the risks due to the volatility of cash flows. The table below summarizes the maturity of the financial liabilities of the Company based on expected payments on undiscounted basic contracts.

	Less than 1 year	From 1 year to 5 years	Total
	VND	VND	VND
<b>As at 30 June 2025</b>			
Loans and debts	51,780,787,055	-	51,780,787,055
Trade payables	23,988,967,140	-	23,988,967,140
Other Payables and accrued expenses	4,499,165,947	-	4,499,165,947
	<b>80,268,920,142</b>	<b>-</b>	<b>80,268,920,142</b>
<b>As at 01 January 2025</b>			
Loans and debts	111,292,692,176	-	111,292,692,176
Trade payables	18,976,823,385	-	18,976,823,385
Other Payables and accrued expenses	3,646,936,836	-	3,646,936,836
	<b>133,916,452,397</b>	<b>-</b>	<b>133,916,452,397</b>

**Collaterals**

The company used fixed tangible assets to secure its loan at banks at 30 June 2025 and 01 January 2025 (refer to Notes 5.8).

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**Fair values and carrying amounts**

	<b>Carrying amount</b>		<b>Fair value</b>	
	<b>30/06/2025</b>	<b>01/01/2025</b>	<b>30/06/2025</b>	<b>01/01/2025</b>
	VND	VND	VND	VND
<b>Financial assets</b>				
Trade receivables	62,535,651,333	107,875,457,413	61,145,027,334	106,921,046,537
Other receivables	806,585,808	404,470,456	806,585,808	404,470,456
Available-for-sales financial assets				
Cash and cash equivalents	13,105,132,737	16,360,889,595	13,105,132,737	16,360,889,595
	<b>76,447,369,878</b>	<b>124,640,817,464</b>	<b>75,056,745,879</b>	<b>123,686,406,588</b>
<b>Financial liabilities</b>				
Loans and debts	51,780,787,055	111,292,692,176	51,780,787,055	111,292,692,176
Trade payables	23,988,967,140	18,976,823,385	23,988,967,140	18,976,823,385
Other payable and accrued expenses	4,499,165,947	3,646,936,836	4,499,165,947	3,646,936,836
	<b>80,268,920,142</b>	<b>133,916,452,397</b>	<b>80,268,920,142</b>	<b>133,916,452,397</b>

The fair value of the financial assets and liabilities was not officially assessed and determined as at 30 June 2025 and 01 January 2025. However, it is Board of General Directors' assessment that the fair values of these financial assets and liabilities are not materially different from their carrying amount at the balance sheet date.

**9. OTHER INFORMATION****9.1 Transactions and balances with related parties**

The related parties with the Company include key management members the individuals involved with key management members and other related parties.

The key management members include members of the Board of Management, Board of Supervisors, the Board of General Directors and Chief Accountant. Individuals associated with key management members are close members in the family of key management members.

The sale and services rendered transactions with key management members and individuals related to key management members don't occur.

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

Income of key management members:

	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
<b>The members of the Board of Management and the Board of General Directors</b>		
Mr. Dang Viet Anh	-	57,500,000
Mr. Le Thanh Tung	757,165,383	706,530,975
Ms. Dang Thi Thu Hang	-	36,000,000
Ms. Ly Thi Xuan Mai	671,827,860	647,088,583
Mr. Luu Hoai Nam	-	42,000,000
Ms. Tran Thi Kieu Tien	-	36,000,000
Mr. Nguyen Quoc Khanh	-	28,500,000
Mr. Thai Van Hung	-	36,000,000
<b>Board of Supervisors</b>		
Mr. Dong Hai Ha	-	28,500,000
Ms. Tran Thi Bich Nhi	-	24,000,000
Mr. Le Van Son	-	9,500,000
<b>Chief Accountant</b>		
Mrs. Le Thi My Tien	216,848,000	238,352,923
	<b>1,645,841,243</b>	<b>1,889,972,481</b>

Main transactions with the related parties:

	Activities	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Ms. Tran Thi Kieu Tien	Disposition of a subsidiary's shares	-	3,300,000,000
		-	<b>3,300,000,000</b>

**9.2 Transactions and balances with other related parties**

Main transactions with the related parties:

Related Company	Activities	From 01/01/2025 to 30/06/2025 VND	From 01/01/2024 to 30/06/2024 VND
Tam sinh nghĩa investment development joint stock company	Selling goods/ services	17,911,449	-
AAA Assurance Corporation	Buying goods/ services	322,731,805	331,474,371
Magnolia Investment Corporation	Buying goods/ services	1,028,419,350	981,785,000

**NOTES TO THE INTERIM FINANCIAL STATEMENT**

For the six-month period ended 30 June 2025

**Balances of receivables, payables with the related parties**

Related Company	Activities	30/06/2025 VND	01/01/2025 VND
<b>Receivables from related parties</b>			
Tam sinh nghia investment development	Trade receivables	19,344,365	-
Magnolia Investment Corporation	Long-term deposit	305,145,000	305,145,000
<b>Payables to related parties</b>			
Magnolia Investment Corporation	Trade payables	378,921,896	-

**9.3 Segment reporting**

Segment information is presented by business segment and geographical area. The primary segment reporting is by geographical area based on the Company's internal organizational structure, management and internal financial reporting system.

We do not present Segment Reports in the interim financial statements because the Board of Directors has assessed and concluded that the Company does not have more than one segment (both business and geographical areas) to report in accordance with the provisions of the Accounting Standards. The Company currently operates mainly in only one field, which is the production and trading of pharmaceuticals and health protection foods, and in only one geographical area, which is Vietnam.

**9.4 Commitments****Operating lease commitment**

The Company is required to make minimum payments under future non-cancelable operating leases as follows:

Index	30/06/2025 VND	01/01/2025 VND
Less than 1 year	1,000,783,350	2,001,566,700
	<b>1,000,783,350</b>	<b>2,001,566,700</b>

**Capital commitment**

Commitments for fixed asset creation expenditures that have been contracted at the end of the accounting period but have not been accounted for in the interim financial statements are as follows:

Index	30/06/2025 VND	01/01/2025 VND
Factory, machinery and equipment	-	319,444,830
	<b>-</b>	<b>319,444,830</b>



## NOTES TO THE INTERIM FINANCIAL STATEMENT

For the six-month period ended 30 June 2025


---

### 9.5 Post balance sheet events

There have been no significant events occurring after the balance sheet date, 30 June 2025, which would require adjustments or disclosures to be made in the interim financial statements.



**PHAM THI THU LANH**  
Preparer



**LE THI MY TIEN**  
Chief Accountant



**LE THANH TUNG**  
General Director  
Dong Thap, 11 August 2025

